| pubmed-article:8740098 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8740098 | lifeskim:mentions | umls-concept:C0002679 | lld:lifeskim |
| pubmed-article:8740098 | lifeskim:mentions | umls-concept:C0011209 | lld:lifeskim |
| pubmed-article:8740098 | lifeskim:mentions | umls-concept:C0238607 | lld:lifeskim |
| pubmed-article:8740098 | lifeskim:mentions | umls-concept:C0220825 | lld:lifeskim |
| pubmed-article:8740098 | lifeskim:mentions | umls-concept:C0201734 | lld:lifeskim |
| pubmed-article:8740098 | lifeskim:mentions | umls-concept:C0205210 | lld:lifeskim |
| pubmed-article:8740098 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:8740098 | pubmed:dateCreated | 1996-10-16 | lld:pubmed |
| pubmed-article:8740098 | pubmed:abstractText | To evaluate the safety, tolerance and pharmacokinetics of a new formulation of amphotericin B (AmB; CAS 1397-89-3) 18 AIDS patients treated for different kinds of mycoses were studied: oropharingeal and/or esophageal azole-resistant candidiasis (9), CNS cryptococcosis (7) or aspergillosis (2). Amphotericin B daily dose was infused in 100 ml of a lipid emulsion. The patients aged from 26 to 54 years with body weight ranging from 42 to 89 kg. Blood samples were collected at fixed intervals and plasma stored at -20 degrees C until tested by a specific HPLC assay. The individual kinetic analysis of plasma drug levels was performed by a two-compartment open model. The data were analyzed using P-Pharm, a computer program designed for population pharmacokinetic analysis that allows pooling of data. The effect of a variety of demographic factors on clearance and volume of distribution was investigated. The clearance and the apparent volume of distribution were, respectively, (mean +/- SD): 0.037 +/- 0.015 l/h/kg and 0.45 +/- 0.32 l/kg. The interindividual variability in AmB clearance and volume of distribution was modelled with proportional error with an estimated coefficient of variation of 40.6% and 70.9%, respectively. Clinical and biological tolerance was very good and no patient experience infusion-related adverse effects or hematologic and hepatic toxicity; a moderate renal failure occurred in only one patient. | lld:pubmed |
| pubmed-article:8740098 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8740098 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8740098 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8740098 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8740098 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8740098 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8740098 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8740098 | pubmed:month | Apr | lld:pubmed |
| pubmed-article:8740098 | pubmed:issn | 0004-4172 | lld:pubmed |
| pubmed-article:8740098 | pubmed:author | pubmed-author:GiacchinoRR | lld:pubmed |
| pubmed-article:8740098 | pubmed:author | pubmed-author:MaseratiRR | lld:pubmed |
| pubmed-article:8740098 | pubmed:author | pubmed-author:VillanoVV | lld:pubmed |
| pubmed-article:8740098 | pubmed:author | pubmed-author:RegazziM BMB | lld:pubmed |
| pubmed-article:8740098 | pubmed:author | pubmed-author:VialePP | lld:pubmed |
| pubmed-article:8740098 | pubmed:author | pubmed-author:AlbericiFF | lld:pubmed |
| pubmed-article:8740098 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8740098 | pubmed:volume | 46 | lld:pubmed |
| pubmed-article:8740098 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8740098 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8740098 | pubmed:pagination | 445-9 | lld:pubmed |
| pubmed-article:8740098 | pubmed:dateRevised | 2009-11-19 | lld:pubmed |
| pubmed-article:8740098 | pubmed:meshHeading | pubmed-meshheading:8740098-... | lld:pubmed |
| pubmed-article:8740098 | pubmed:meshHeading | pubmed-meshheading:8740098-... | lld:pubmed |
| pubmed-article:8740098 | pubmed:meshHeading | pubmed-meshheading:8740098-... | lld:pubmed |
| pubmed-article:8740098 | pubmed:meshHeading | pubmed-meshheading:8740098-... | lld:pubmed |
| pubmed-article:8740098 | pubmed:meshHeading | pubmed-meshheading:8740098-... | lld:pubmed |
| pubmed-article:8740098 | pubmed:meshHeading | pubmed-meshheading:8740098-... | lld:pubmed |
| pubmed-article:8740098 | pubmed:meshHeading | pubmed-meshheading:8740098-... | lld:pubmed |
| pubmed-article:8740098 | pubmed:meshHeading | pubmed-meshheading:8740098-... | lld:pubmed |
| pubmed-article:8740098 | pubmed:meshHeading | pubmed-meshheading:8740098-... | lld:pubmed |
| pubmed-article:8740098 | pubmed:meshHeading | pubmed-meshheading:8740098-... | lld:pubmed |
| pubmed-article:8740098 | pubmed:meshHeading | pubmed-meshheading:8740098-... | lld:pubmed |
| pubmed-article:8740098 | pubmed:meshHeading | pubmed-meshheading:8740098-... | lld:pubmed |
| pubmed-article:8740098 | pubmed:meshHeading | pubmed-meshheading:8740098-... | lld:pubmed |
| pubmed-article:8740098 | pubmed:year | 1996 | lld:pubmed |
| pubmed-article:8740098 | pubmed:articleTitle | Clinical and pharmacokinetic evaluation of a new lipid-based delivery system of amphotericin B in AIDS patients. | lld:pubmed |
| pubmed-article:8740098 | pubmed:affiliation | Pharmacology Department, S. Matteo Hospital, Pavia, Italy. | lld:pubmed |
| pubmed-article:8740098 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8740098 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8740098 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8740098 | lld:pubmed |
